Core Viewpoint - Shengnuo Bio (688117) expects to achieve a net profit attributable to shareholders of the parent company between 152 million and 190 million yuan for the fiscal year 2025, representing a year-on-year increase of 204.42% to 280.53% [1] Group 1 - The company is focusing on its annual business strategy while advancing the construction of its production capacity [1] - There is a continuous expansion of both domestic and international markets, leading to sustained growth in demand for the company's peptide raw material business [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2026-001 成都圣诺生物科技股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 公司上年同期利润总额为 6,150.86 万元，归属于母公司所有者的净利润为 5,002.37 万元，归属于母公司所有者扣除非经常性损益后的净利润为 4,561.24 万 元，基本每股收益为 0.45 元。 三、本期业绩变化的主要原因 报告期内，公司紧密围绕年度经营战略，推进在建产能落地的同时，持续开 拓国内外市场，使得公司多肽原料药业务订单需求持续增长，带动公司整体业绩 稳步提升，较上年同期业绩实现大幅增长，进一步增强公司在多肽医药市场的全 球化竞争力。 1 四、风险提示 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，成都圣诺生物科技股份有限公司（以下简称"公 司"）预计 2025 年度实现归属于母公司所有者的净利润 15,228.31 万元 ...

每经AI快讯，1月15日，圣诺生物(688117.SH)发布2025年度业绩预告，预计归属于母公司所有者的净利 润为1.52亿元至1.90亿元，与上年同期相比增加204.42%至280.53%。报告期内，公司推进在建产能落 地，持续开拓国内外市场，多肽原料药业务订单需求增长，带动整体业绩大幅提升。 ...

21智讯1月15日电，圣诺生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 15,228.31万元至19,035.38万元，同比预增204.42%—280.53%；预计2025年全年归属于上市公司股东的 扣除非经常性损益的净利润为14,872.70万元至18,590.88万元，同比预增226.07%—307.58%，报告期 内，公司紧密围绕年度经营战略，推进在建产能落地的同时，持续开拓国内外市场，使得公司多肽原料 药业务订单需求持续增长，带动公司整体业绩稳步提升，较上年同期业绩实现大幅增长，进一步增强公 司在多肽医药市场的全球化竞争力。 ...

圣诺生物公告，预计2025年度实现归属于母公司所有者的净利润1.52亿元至1.9亿元，与上年同期相比， 将增加1.02亿元至1.4亿元，同比增加204.42%至280.53%；预计2025年度实现归属于母公司所有者的扣 除非经常性损益的净利润1.49亿元至1.86亿元，与上年同期相比，将增加1.03亿元至1.4亿元，同比增加 226.07%至307.58%。报告期内，公司紧密围绕年度经营战略，推进在建产能落地的同时，持续开拓国 内外市场，使得公司多肽原料药业务订单需求持续增长，带动公司整体业绩稳步提升，较上年同期业绩 实现大幅增长，进一步增强公司在多肽医药市场的全球化竞争力。 ...

（文章来源：第一财经） 圣诺生物发布2025年度业绩预告，预计归属于母公司所有者的净利润为1.52亿元至1.90亿元，与上年同 期相比增加204.42%至280.53%。 ...

特别风险提示： 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都 圣诺生物制药有限公司（以下简称"圣诺制药"）前期与某客户签订了日常经营 销售合同，该合同为达成合作的意向性框架合同，合同中约定的采购金额为预测 值，且合同的具体执行情况需根据交易双方实际签署的采购订单予以确定；截止 目前，受合同方终端客户产品商业化进展较预期滞后情况的影响，未实际履行产 品商业化订单，使得合同履行进展不达预期。 该框架合同的签订属于公司日常经营行为，合同履行期限届满事项不会 对公司本年度经营业绩或财务状况产生重大不利影响，不存在损害公司及全体股 东利益的情况。 公司目前已收到终端客户后续合作意向，但尚未与其签订正式合同，未 来年度与相关客户产生的采购金额及利润贡献暂时无法预计，敬请广大投资者注 意投资风险。 证券代码：688117 证券简称：圣诺生物 公告编号：2025-042 成都圣诺生物科技股份有限公司 关于全资子公司日常经营重大合同的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述框架合同属于子公司与客户为开 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shengnuo Pharmaceutical, has signed a framework contract to supply GLP-1 peptide raw materials, with a total contract value not exceeding RMB 350 million, effective until December 31, 2025 [1] Group 1 - The contract was signed with a customer for the supply of GLP-1 peptide raw materials [1] - The total contract amount is capped at RMB 350 million, including tax [1] - The performance period of the contract extends from the signing date until December 31, 2025 [1] Group 2 - The company is actively promoting the cooperation process following the contract signing [1] - The progress of the contract's execution has been delayed due to the slow commercialization of the end customer's products [1] - The company believes there is a risk that the framework contract may not be fully executed [1]

Core Insights - The article discusses the registration and quality management system assessments for medical devices in Guangdong Province, highlighting various companies and their products that have undergone evaluations and received approvals or required modifications [2][5]. Group 1: Company Registrations - Guangdong Weinuodun Medical Technology Co., Ltd. received approval for its medical ozone therapy device on November 3, 2025 [3]. - Guangdong Baisheng Medical Instrument Co., Ltd. passed the evaluation for high-frequency surgical equipment on November 3, 2025 [3]. - Shenzhen Kefu Biotechnology Co., Ltd. was approved for its continuous glucose monitoring system on November 4, 2025 [3]. - Guangzhou Wanfu Biological Technology Co., Ltd. received approval for its hepatitis B virus nucleic acid testing kit on November 10, 2025 [3]. - Shenzhen Karman Medical Equipment Co., Ltd. was approved for its intracranial pressure sensor and cerebrospinal fluid drainage set on November 12, 2025 [3]. Group 2: Quality Management System Assessments - The Guangdong Provincial Drug Administration is implementing a quality management system assessment for Class II medical devices, with results communicated to applicants via SMS or web queries since May 2022 [5]. - Companies such as Shenzhen Aibo Hechuang Medical Robot Co., Ltd. received approval for their vascular intervention surgery control system on November 27, 2025 [5]. - Guangdong Tiancheng Tianmei Medical Technology Co., Ltd. was approved for absorbable surgical sutures on November 19, 2025 [4].

Group 1 - The core announcement is that Shengnuo Biotech has appointed three new vice presidents: Ms. Wang Xiaoli, Mr. Lu Changliang, and Mr. Ma Zhonggang [2]